Association of statin use with cataracts a propensity score-matched analysis

JAMA Ophthalmology

Volumn 131, Issue 11, 2013, Pages 1427-1434

  Leuschen, Jessica ^a,b   Mortensen, Eric M ^c,d   Frei, Christopher R ^e,f   Mansi, Eva A ^h   Panday, Vasudha ^a,b,g   Mansi, Ishak ^c,d  

^a WILFORD HALL MEDICAL CENTER   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^h Ramad Hospital   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROMYCIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CATARACT; CHARLSON COMORBIDITY INDEX; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMORBIDITY; COMPARATIVE STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK FACTOR; SCLEROSIS; SECONDARY ANALYSIS; SUBCAPSULAR CATARACT;

CARDIOVASCULAR DISEASES; CATARACT; CHOLESTEROL, LDL; COHORT STUDIES; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MILITARY MEDICINE; ODDS RATIO; PROPENSITY SCORE; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84888217467     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.4575     Document Type: Article

References (42)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844-851.
2. Salm M, Belsky D, Sloan FA. Trends in cost of major eye diseases to Medicare, 1991 to 2000. Am J Ophthalmol. 2006;142(6):976-982.
3. Brenner MH, Curbow B, Javitt JC, Legro MW, Sommer A. Vision change and quality of life in the elderly: response to cataract surgery and treatment of other chronic ocular conditions. Arch Ophthalmol. 1993;111(5):680-685.
4. American Academy of Ophthalmology. Preferred Practice Patterns guidelines. 2008. http://one.aao.org/CE/PracticeGuidelines/PPP.aspx. Accessed September 9, 2012.
5. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol. 1999;10(6):543-559.
6. Fong DS, Poon KY. Recent statin use and cataract surgery. Am J Ophthalmol. 2012;153(2):222-228.e1.
7. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
8. Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol. 1996;40(4):320-337.
9. Chodick G, Heymann AD, Flash S, Kokia E, Shalev V. Persistence with statins and incident cataract: a population-based historical cohort study. Ann Epidemiol. 2010;20(2):136-142.
10. Blaha MJ, Nasir K, Blumenthal RS. Statin therapy for healthy men identified as "increased risk." JAMA. 2012;307(14):1489-1490.
11. Redberg RF, Katz MH. Healthy men should not take statins. JAMA. 2012;307(14):1491-1492.
12. Kugler J. Military Health System Patient Centered Medical Home guide: Tricare-Office of the Chief Medical Officer, Department of Defense. June 2011. http://www.tricare.mil/tma/ocmo/download/MHSPCMHGuide.pdf.
13. Tricare Management Activity. M2 functional specifications. http://tricare.mil/tma/dhcape/data/m2.aspx. Accessed September 25, 2013.
14. Luhrman S, Lehr E, Hefflin C, Saund N. Interface Control Document Describing the Case Management Exchange from BEA to MDR and M2 Baseline: DHSS Program Management. August 18, 2008 edition. Falls Church, VA: Defense Health Services Systems; 2008.
15. Enewold L, Brinton LA, McGlynn KA, Zahm SH, Potter JF, Zhu K. Oral contraceptive use among women in themilitary and the general US population. JWomens Health (Larchmt). 2010;19(5):839-845.
16. Moniz C. Outpatient Workload (RVU) Predictors: Age, Gender & Beneficiary Category. Baltimore, MD: US Army Medical Department Center and School; 2008.
17. Gantt CJ, Neely JA, Villafana IA, Chun CS, Gharabaghli SM. Analysis of weight and associated health consequences of the active duty staff at a major Naval medical center. Mil Med. 2008;173(5):434-440.
18. George SZ, Childs JD, Teyhen DS, et al. Brief psychosocial education, not core stabilization, reduced incidence of low back pain: results from the Prevention of Low Back Pain in the Military (POLM) cluster randomized trial. BMC Med. 2011;9(1):128.
19. Elmitwalli T, Otterpohl R. Grey water treatment in upflow anaerobic sludge blanket (UASB) reactor at different temperatures. Water Sci Technol. 2011;64(3):610-617.
20. Mansi I, Frei CR, Pugh MJ, Mortensen EM. Psychologic diseases and statin use: a propensity score-matched analysis. Pharmacotherapy. 2013;33(6):615-626.
21. US Agency for Healthcare Research and Quality. Clinical Classifications Software (CCS) for ICD-9-CM. http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs. jsp. Accessed January 1, 2012.
22. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
23. Selim AJ, Fincke G, Ren XS, et al. Comorbidity assessments based on patient report: results from the Veterans Health Study. J Ambul Care Manage. 2004;27(3):281-295.
24. Mansi I, Frei CR, Pugh J, Makris U, Mortensen EM. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med. 2013;173(14):1318-1326.
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
26. Grundy SM, Cleeman JI, Merz CN, et al Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-732.
27. Kanski JJ, Bowling B. Clinical Ophthalmology: A Sytematic Approach. 7th ed. Philadelphia, PA: Elsevier; 2011.
28. US Food and Drug Administration. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. 2011. http://www.fda.gov/Drugs/DrugSafety/ ucm256581.htm. Accessed June 15, 2011.
29. Becker S, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J. 2002;2(4):358-377.
30. Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing: version 4.0.5 ed. 2003. http://ideas.repec.org/c/boc/bocode/s432001. html.
31. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use and fracture risk: study of a US veterans population. Arch Intern Med. 2005;165(17):2007-2012.
32. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373-418.
33. Mori M, Li G, Abe I, et al. Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat. J Clin Invest. 2006;116(2):395-404.
34. Zakrzewski P, Milewska J, Czerny K. The eye lens evaluation of the atorvastatin-treated white rat. Ann Univ Mariae Curie Sklodowska Med. 2002;57(2):165-171.
35. Tan JS, Mitchell P, Rochtchina E, Wang JJ. Statin use and the long-term risk of incident cataract: the Blue Mountains Eye Study. Am J Ophthalmol. 2007;143(4):687-689.
36. Klein BE, Klein R, Lee KE, Grady LM. Statin use and incident nuclear cataract. JAMA. 2006;295(23):2752-2758.
37. Machan CM, Hrynchak PK, Irving EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci. 2012;89(8):1165-1171.
38. Smeeth L, Hubbard R, Fletcher AE. Cataract and the use of statins: a case-control study. QJM. 2003;96(5):337-343.
39. Waudby CJ, Berg RL, Linneman JG, et al. Cataract research using electronic health records. BMC Ophthalmol. 2011;11:32.
40. Schlienger RG, Haefeli WE, Jick H, Meier CR. Risk of cataract in patients treated with statins. Arch Intern Med. 2001;161(16):2021-2026.
41. Harris ML, Bron AJ, Brown NA, et al Oxford Cholesterol Study Group. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Br J Ophthalmol. 1995;79(11):996-1002.
42. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119(15):2051-2057.